| P50 | author | Raffaele Capasso | Q42411082 |
| | Angelo A. Izzo | Q42411084 |
| | Giovanni Marsicano | Q54283626 |
| | Vincenzo Di Marzo | Q29642556 |
| P2093 | author name string | Pierangelo Orlando | |
| | Stefania Petrosino | |
| | Beat Lutz | |
| | Santosh Nigam | |
| | Francesca Borrelli | |
| | Gabriella Aviello | |
| | Francesco Capasso | |
| | Endocannabinoid Research Group | |
| P2860 | cites work | Caspase inhibitors promote alternative cell death pathways | Q36633894 |
| | Genetic testing for colon cancer | Q36666308 |
| | The endogenous cannabinoid system protects against colonic inflammation | Q37370275 |
| | The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. | Q40385552 |
| | Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. | Q40789377 |
| | Endocannabinoid overactivity and intestinal inflammation | Q42844245 |
| | The cannabinoid receptor antagonist SR 141716 prevents acquisition of drinking behavior in alcohol-preferring rats | Q43800999 |
| | The endogenous cannabinoid system controls extinction of aversive memories | Q44085607 |
| | Possible endocannabinoid control of colorectal cancer growth | Q44569526 |
| | Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes | Q44807851 |
| | Fatty acid amide hydrolase controls mouse intestinal motility in vivo | Q46687826 |
| | Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation | Q46887706 |
| | Development of the first potent and specific inhibitors of endocannabinoid biosynthesis | Q46934838 |
| | Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels | Q48518739 |
| | Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase | Q48789988 |
| | Cytoskeleton out of the cupboard: colon cancer and cytoskeletal changes induced by loss of APC. | Q52002352 |
| | Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats | Q60690593 |
| | The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract | Q22252801 |
| | Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase | Q24555807 |
| | The endocannabinoid system as an emerging target of pharmacotherapy | Q24648473 |
| | A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding | Q25938984 |
| | Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity | Q33921608 |
| | A new strategy to block tumor growth by inhibiting endocannabinoid inactivation | Q34338108 |
| | Aberrant crypt foci of the colon as precursors of adenoma and cancer | Q34477507 |
| | The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen | Q34479461 |
| | Cannabinoids and cancer: pros and cons of an antitumour strategy | Q35100892 |
| | Effect of olive oil on early and late events of colon carcinogenesis in rats: modulation of arachidonic acid metabolism and local prostaglandin E(2) synthesis | Q35359099 |
| | Aberrant crypt foci as microscopic precursors of colorectal cancer | Q35605612 |
| | CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents. | Q35781582 |
| | Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents | Q35795304 |
| | Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation | Q35803526 |
| | The endocannabinoid system and its therapeutic exploitation | Q35876026 |
| | The gastrointestinal pharmacology of cannabinoids: an update. | Q35938724 |
| | Recent advances in understanding the cell death pathways activated by anticancer therapy | Q36059491 |
| | Aberrant crypt foci. | Q36395469 |
| | Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids | Q36439301 |
| | Modulators of endocannabinoid enzymic hydrolysis and membrane transport. | Q36441184 |
| | Effects on cell viability. | Q36441223 |
| P433 | issue | 1 | |
| P921 | main subject | N-arachidonoylserotonin | Q4783529 |
| | endocannabinoids | Q10483908 |
| P304 | page(s) | 89-98 | |
| P577 | publication date | 2007-09-06 | |
| P1433 | published in | Journal of Molecular Medicine | Q6295593 |
| P1476 | title | Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon | |
| P478 | volume | 86 | |